REPLReplimune Group, Inc.

REPL Stock Price, Valuation & Chart | Replimune Group, Inc.

Compare

$15.980+0.31 (+1.98%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology REPL intrinsic value REPL calculated fair value vs price

Overview Financials Dividends Ratios

REPL Historical price chart

REPL Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.34B

PE Ratio-5.07

EPS-3.15

Trading Volume1.99M

Today's High/Low16.33/15.5

Dividend Yield0.00

52 Week High/Low16.33/1.5

Shares Outstanding84.03M

REPL Financial Statement

REPL Analyst ratings

REPL Analysis & performance metrics

REPL Company profile

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop…

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II…

REPL Management team

Name

Position

Konstantinos Xynos M.B.A., M.D., Ph.D.

Chief Medical Officer

Nina Aragam

Senior Vice President of Portfolio Strategy & Program Management

Paul Bullock

Chief Manufacturing Officer & Framingham Site Head

Philip Astley-Sparke F.S.A.

Executive Chairman

Sushil Patel Ph.D.CEO

Chief Executive Officer & Director

Camilo Garcia M.A., M.B.A.

Chief Human Resource Officer

Shawn Glidden J.D.

Senior Vice President of General Counsel

Emily Luisa HillCFO

Chief Financial Officer

Name

Position

Konstantinos Xynos M.B.A., M.D., Ph.D.

Chief Medical Officer

Nina Aragam

Senior Vice President of Portfolio Strategy & Program Management

Paul Bullock

Chief Manufacturing Officer & Framingham Site Head

Philip Astley-Sparke F.S.A.

Executive Chairman

Sushil Patel Ph.D.CEO

Chief Executive Officer & Director

Camilo Garcia M.A., M.B.A.

Chief Human Resource Officer

Shawn Glidden J.D.

Senior Vice President of General Counsel

Emily Luisa HillCFO

Chief Financial Officer

Management Team

Konstantinos Xynos M.B.A., M.D., Ph.D.

Chief Medical Officer

Nina Aragam

Senior Vice President of Portfolio Strategy & Program Management

Paul Bullock

Chief Manufacturing Officer & Framingham Site Head

Philip Astley-Sparke F.S.A.

Executive Chairman

Sushil Patel Ph.D.CEO

Chief Executive Officer & Director

Camilo Garcia M.A., M.B.A.

Chief Human Resource Officer

Shawn Glidden J.D.

Senior Vice President of General Counsel

Emily Luisa HillCFO

Chief Financial Officer

Management

Konstantinos Xynos M.B.A., M.D., Ph.D.

Chief Medical Officer

Nina Aragam

Senior Vice President of Portfolio Strategy & Program Management

Paul Bullock

Chief Manufacturing Officer & Framingham Site Head

Philip Astley-Sparke F.S.A.

Executive Chairman

Sushil Patel Ph.D.CEO

Chief Executive Officer & Director

Camilo Garcia M.A., M.B.A.

Chief Human Resource Officer

Shawn Glidden J.D.

Senior Vice President of General Counsel

Emily Luisa HillCFO

Chief Financial Officer

Total 8 executives

REPL Frequently asked questions

What is Replimune Group, Inc. (REPL) Stock Price?

Current stock price of Replimune Group, Inc. (REPL) stock is $15.980. The stock price is +1.98% higher in the session. The intraday range can be seen from this page. Volume of Replimune Group, Inc. (REPL) stock is 1.99M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Replimune Group, Inc. (REPL) stock price going up or down today?

The stock price of Replimune Group, Inc. (REPL) can change with earnings, company news, and overall market sentiment. Replimune Group, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Replimune Group, Inc. stock expensive at its current price?

Whether Replimune Group, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for REPL on this page is -5.07. EPS on this page is -3.15. Compare those figures with peers and growth expectations before deciding if the current Replimune Group, Inc. price is justified.

How has the stock price of Replimune Group, Inc. (REPL) performed historically?

Historical performance for Replimune Group, Inc. (REPL) is shown on the price chart on this page. Review multi-period moves alongside volume to see how REPL reacted to past earnings and market events.

Should I buy Replimune Group, Inc. (REPL) stock, at this price?

Buying Replimune Group, Inc. (REPL) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.